Arcutis Biotherapeutics

Arcutis Biotherapeutics has built one of the cleanest commercial-stage specialty pharma stories in dermatology — and the market is still pricing it like an unprofitable clinical-stage company. The lead product ZORYVE (roflumilast topical) is now approved across three indications: plaque psoriasis cream (approved 2022), seborrheic dermatitis foam (2023), and atopic dermatitis cream (Q1/2024). The third indication, atopic dermatitis pediatric expansion (down to 6 years), launched in late 2025 and is driving the inflection.

Q1/2026 revenue grew 60.1% YoY to $122M, putting ZORYVE on an annualized run rate of approximately $1.0 billion. Gross margin sits at 90.9% (typical for a specialty topical with manufacturer-controlled distribution), and operating margin has narrowed to -8.6% from -45% in 2024. The Q3/Q4 2026 GAAP-profitability milestone, telegraphed by management, would be the catalytic narrative inflection that moves Arcutis from speculative biotech to high-quality commercial-stage compounder.

The 14.4% short interest is the contradiction: bears argue that (1) the Otezla (apremilast) generic launch in 2025 created low-cost competition for moderate psoriasis, (2) JAK-inhibitor topicals (Opzelura) take the most severe AD share, and (3) ZORYVE pricing power will eventually erode. Each is a real risk but the volume growth is currently overwhelming them.

Arcutis's institutional ownership is the most encouraging signal for the bull thesis. Baker Brothers Advisors (Felix and Julian Baker) hold 13.8% of shares outstanding, making them the largest single holder — the Bakers have a multi-decade track record of dermatology IP picks (they were early in Otonomy, Cassava Sciences, and several dermatology mid-caps). Perceptive Advisors (Joe Edelman) holds 4.7% and added in Q4/2025. OrbiMed Advisors sits at 3.9%.

The big tell is Vivo Capital, a healthcare-only crossover fund that opened a fresh 2.1M-share position in Q1/2026 — Vivo specifically called out Arcutis in their Q1 letter as a textbook example of a commercial-stage dermatology asset transitioning to GAAP profitability ahead of street estimates.

On the bear side, Citadel reported a 1.4M-share short, and Marshall Wace initiated a short in March 2026. The 14.4% short interest creates squeeze setup potential on any positive GAAP-profitability or pediatric atopic dermatitis script-tracker beat.

Insider activity is quiet: CEO Frank Watanabe sold 25,000 shares in March under 10b5-1 plan (routine). No notable insider purchases in the past 18 months — would be more bullish to see open-market buying ahead of the targeted Q3/Q4 GAAP inflection.

Arcutis trades at 18.5x forward earnings (based on H2/2026 GAAP-profitable estimates), 6.4x EV/Sales, and 5.1x EV/Forward-Sales. Specialty dermatology peers: Krystal Biotech (9x EV/Sales), Verrica (4x EV/Sales), Almirall (3x EV/Sales, but legacy commercial). The DCF case with 35% revenue growth fading to 8% terminal, 11% WACC, and 30% steady-state operating margin (achievable given 90% gross margin) gives fair value of $42 — implying 97% upside from $21.32. The sell-side consensus mean target is $34.62, implying 62% upside. The bear case (ZORYVE growth halves to 25%, GAAP profitability pushed to 2028, dilutive raise required) yields $11. Position sizing matters here: the 90% gross margin and Baker Brothers concentration suggest the bull case is more likely, but the binary nature of GAAP-profitability timing means full position is premature.

1. August 6, 2026: Q2/2026 earnings — ZORYVE script trajectory and operating expense discipline; pre-GAAP-profitability bridge math
2. Q3 2026 (estimated): Pediatric atopic dermatitis 6-month script tracker mature data — defines 2027 revenue baseline
3. Q4 2026 (targeted): GAAP profitability inflection — binary narrative catalyst that re-rates the multiple

Arcutis is the kind of asymmetric commercial-stage biotech setup I look for — 60% revenue growth, 90% gross margin, a clear path to GAAP profitability within 2-3 quarters, and Baker Brothers as the largest concentrated holder. The bear case (competition from generic Otezla and Opzelura, dilutive raise risk) is real but each can be quantified and tracked. My approach: 1.5% portfolio position at $20-$23 range, with a clear plan to add 1% on any pullback below $17 on Q2 expense surprise, and trim above $32 only if the GAAP-profitability slips beyond Q1/2027. The Baker Brothers concentration is the deciding factor — when the largest dermatology-IP-savvy specialist holds 13.8%, the floor under the equity is meaningfully different from typical commercial-stage biotech.